Citations

Showing 10 of 108119 citations.

Cardiac magnetic resonance in patients with elevated troponin and normal coronary angiography
Bhatia, Subir , Anstine, Christopher V. , Jaffe, Allan S. , Chandrasekaran, Krishnaswamy , Foley, Thomas A. , Hodge, David O. , Anavekar, Nandan S., Anstine, Christopher, Hodge, David, Jaffe, Allan S. , Gersh, Bernard J.

Mayo Clinic

Heart | April 4, 2019 | Volume: 105 | Issue: 16 | Pages: 1231-1236

10.1136/heartjnl-2018-314631 | PMID 30948519 Get It

Background Invasive angiography in the setting of cardiac troponin elevation may reveal non-obstructive coronary arteries leading to uncertainty in diagnosis. Cardiac MR (CMR) may aid in diagnosis, however, the spectrum of diagnostic findings in the patient presenting with symptoms of cardiac ischaemia, elevated cardiac biomarkers and a negative invasive coronary angiogram is yet to be completely described. Methods We queried the Mayo Clinic, Rochester inpatient record from 1 January 2000 to 31 December 2016 to identify patients who: (1) had an elevated troponin T during admission, (2) underwent coronary angiography within 30 days of troponin T elevation which was considered negative for obstructive coronary arterial disease and (3) underwent CMR within 30 days of troponin T elevation. CMR diagnoses were classified as either (1) myocarditis, (2) small area myocardial infarction, (3) stress cardiomyopathy, (4) non-ischaemic cardiomyopathy or (5) normal. Results Of 215 patients, the spectrum of disease seen on CMR was myocarditis (32%), small area infarction (22%), non-ischaemic cardiomyopathy (20%) and stress cardiomyopathy (9.3%). Conclusion In the largest single-centre study assessing the role of CMR in patients admitted with elevated troponin T with a non-obstructive coronary disease on an angiogram, small area infarction was seen in 22% of patients.
Effect of Collaborative Telerehabilitation on Functional Impairment and Pain Among Patients With Advanced-Stage Cancer
Moynihan, Timothy J. , Loprinzi, Charles L. , Kroenke, Kurt , Moynihan, Timothy, Loprinzi, Charles, Cheville, Andrea , Herrin, Jeph

Mayo Clinic

JAMA Oncology | April 4, 2019 | Volume: 5 | Issue: 5 | Pages: 644

10.1001/jamaoncol.2019.0011 | PMID 30946436 Get It

Optimum age for performing Fontan operation in patients with univentricular heart
Akintoye, Emmanuel , Veldtman, Gruschen , Miranda, William R. , Connolly, Heidi M. , Egbe, Alexander C. , Egbe, Alexander C.

Mayo Clinic

Congenital Heart Disease | April 4, 2019 | Volume: 14 | Issue: 2 | Pages: 138-139

10.1111/chd.12690 | PMID 30945806 Get It

Synonymous but Not Silent: A Synonymous VHL Variant in Exon 2 Confers Susceptibility to Familial Pheochromocytoma and von Hippel-Lindau Disease
Flores, Shahida K., Cheng, Ziming , Jasper, Angela M. , Natori, Keiko, Okamoto, Takahiro , Tanabe, Akiyo , Gotoh, Koro , Shibata, Hirotaka , Sakurai, Akihiro , Nakai, Takuya , Wang, Xiaojing , Zethoven, Magnus, Balachander, Shiva , Aita, Yuichi, Takekoshi, Kazuhiro, Nakamura, Eijiro , Tothill, Richard W. , Aguiar, Ricardo C.T. , Dahia, Patricia L M , Young, William F. , Zheng, Siyuan , Dahia, Patricia L. M.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | April 4, 2019 | Volume: 104 | Issue: 9 | Pages: 3826-3834

10.1210/jc.2019-00235 | PMID 30946460 Get It

Abstract Context von Hippel-Lindau (VHL) disease, comprising renal cancer, hemangioblastoma, and/or pheochromocytoma (PHEO), is caused by missense or truncating variants of the VHL tumor-suppressor gene, which is involved in degradation of hypoxia-inducible factors (HIFs). However, the role of synonymous VHL variants in the disease is unclear. Objective We evaluated a synonymous VHL variant in patients with familial PHEO or VHL disease without a detectable pathogenic VHL mutation. Design We performed genetic and transcriptional analyses of leukocytes and/or tumors from affected and unaffected individuals and evaluated VHL splicing in existing cancer databases. Results We identified a synonymous VHL variant (c.414A>G, p.Pro138Pro) as the driver event in five independent individuals/families with PHEOs or VHL syndrome. This variant promotes exon 2 skipping and hence, abolishes expression of the full-length VHL transcript. Exon 2 spans the HIF-binding domain required for HIF degradation by VHL. Accordingly, PHEOs carrying this variant display HIF hyperactivation typical of VHL loss. Moreover, other exon 2 VHL variants from the The Cancer Genome Atlas pan-cancer datasets are biased toward expression of a VHL transcript that excludes this exon, supporting a broader impact of this spliced variant. Conclusion A recurrent synonymous VHL variant (c.414A>G, p.Pro138Pro) confers susceptibility to PHEO and VHL disease through splice disruption, leading to VHL dysfunction. This finding indicates that certain synonymous VHL variants may be clinically relevant and should be considered in genetic testing and surveillance settings. The observation that other coding VHL variants can exclude exon 2 suggests that dysregulated splicing may be an underappreciated mechanism in VHL-mediated tumorigenesis.
Лечение токсических побочных эффектов у пациентов с распространенным медуллярным раком щитовидной железы
Brose, Marcia S. , Bible, Keith C. , Grande, Carolyn, Chow, Laura Q.M. , Gilbert, J., Worden, Francis P. , Haddad, Robert I.

Mayo Clinic

Head and neck tumors (HNT) | April 4, 2019 | Volume: 9 | Issue: 1 | Pages: 51-67

10.17650/2222-1468-2019-9-1-51-67 Get It

Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy
Tschautscher, Marcella , Jevremović, Dragan , Rajkumar, S. Vincent , Lacy, Martha Q. , Gertz, Morie A. , Dingli, David , Hwa, Yi L. , Fonder, Amie , Hobbs, Miriam, Hayman, Suzanne R. , Zeldenrust, Steven R., Lust, John A., Russell, Stephen J. , Kapoor, Prashant , Lin, Yi , Kourelis, Taxiarchis , Warsame, Rahma , Kyle, Robert A. , Kumar, Shaji , Kaddoura, Marcella , Rajkumar, S Vincent , Gertz, Morie A , Buadi, Francis K. , Fonder, Amie L, Leung, Nelson , Gonsalves, Wilson , Kourelis, Taxiarchis , Warsame, Rahma , Russell, Stephen J , Jevremovic, Dragan , Dingli, David , Lin, Yi , Dispenzieri, Angela , Leung, Nelson , Go, Ronald S. , Gonsalves, Wilson I.

Mayo Clinic

American Journal of Hematology | April 4, 2019 | Volume: 94 | Issue: 7 | Pages: 751-756

10.1002/ajh.25481 | PMID 30945330 Get It

AbstractAchievement of a complete response has been associated with improved outcomes in patients with multiple myeloma. Recently, increasing application of minimal residual disease (MRD) assessment has shown that MRD negativity is a powerful prognostic factor for survival outcomes. We wanted to examine the impact of the polyclonal plasma cell (pPC) compartment among patients in complete response (CR) but are MRD positive. This is a retrospective cohort study where 460 myeloma patients were identified who met criteria for CR and had multicolor flow cytometry performed on the bone marrow (BM). Monoclonal and pPCs were estimated during MRD testing. Final outcomes including overall survival (OS) and time to next treatment (TTNT) were compared among the groups. The median OS for the entire cohort was not reached (95% CI; 63 mos, NR) and the median TTNT was 31 months (95% CI; 27,36). Among the MRDneg group, median TTNT was 37.6 months vs 23 months for MRDpos patients (P < .001); the median OS was not reached for either group, but there was a trend toward better survival for MRDneg patients. Among the MRDpos group, median percentage of pPCs was 65% (2.5–98.5), and those with >95% pPCs had a significantly better TTNT (NR vs 23 months; P = .02) and a trend toward better OS. We conclude that achievement of MRD negativity predicts for better response durability and trend toward improved OS and an increased proportion of pPC predicts for better outcomes within those who have residual tumor cells highlighting the importance of marrow normalization.
Hypereosinophilia in a Patient with Metastatic Non-Small-Cell Lung Cancer Treated with Antiprogrammed Cell Death 1 (anti-PD-1) Therapy
Lou, Yanyan , Marin‐Acevedo, Julian A. , Vishnu, Prakash , Dholaria, Bhagirathbhai , Soyano, Aixa , Knutson, Keith L. , Manochakian, Rami , Dholaria, Bhagirathbhai R , Vishnu, Prakash , Soyano, Aixa , Luo, Yan , Zhang, Yan , Knutson, Keith L.

Mayo Clinic

Immunotherapy | April 4, 2019 | Volume: 11 | Issue: 7 | Pages: 577-584

10.2217/imt-2018-0128 | PMID 30943864 Get It

Tuberculosis in the United States: Medical Consultation Services Provided by 5 Tuberculosis Regional Training and Medical Consultation Centers, 2013–2017
Goswami, Neela D. , Mase, Sundari , Griffith, David E. , Bhavaraju, Rajita, Lardizabal, Alfred , Lauzardo, Michael , Chen, Lisa , Wilson, John , Chappelle, Courtney, Haley, Connie A.

Mayo Clinic

Open Forum Infectious Diseases | April 4, 2019 | Volume: 6 | Issue: 6 | Pages: No page available

10.1093/ofid/ofz167 | PMID 31205971 Get It

Abstract With only 9105 new US tuberculosis (TB) cases reported in 2017, expert consultation is essential for TB care. Data were captured 2013–2017 from consultations by 5 CDC-funded centers, now the TB Centers of Excellence (COEs). 14 586 consultations were provided to TB providers, most related to TB disease and treatment regimens.
Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non–Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial
Bezjak, Andrea , Paulus, Rebecca , Gaspar, Laurie E., Timmerman, Robert , Straube, William L., Ryan, William F., Garces, Yolanda I. , Pu, Anthony T. , Singh, Anurag K. , Videtic, Gregory M.M. , McGarry, Ronald C., Iyengar, Puneeth , Urbanic, James J., Sun, A. , Daly, Megan E. , Grills, Inga S., Sperduto, Paul W. , Bradley, Jeffrey D. , Choy, Hak, Bradley, Jeffrey , Paulus, Rebecca , Ryan, William F., Pantarotto, Jason R. , Normolle, Daniel Paul

Mayo Clinic

Journal of Clinical Oncology | April 3, 2019 | Volume: 37 | Issue: 15 | Pages: 1316-1325

10.1200/jco.18.00622 | PMID 30943123 Get It

PURPOSE Patients with centrally located early-stage non–small-cell lung cancer (NSCLC) are at a higher risk of toxicity from high-dose ablative radiotherapy. NRG Oncology/RTOG 0813 was a phase I/II study designed to determine the maximum tolerated dose (MTD), efficacy, and toxicity of stereotactic body radiotherapy (SBRT) for centrally located NSCLC. MATERIALS AND METHODS Medically inoperable patients with biopsy-proven, positron emission tomography–staged T1 to 2 (≤ 5 cm) N0M0 centrally located NSCLC were accrued into a dose-escalating, five-fraction SBRT schedule that ranged from 10 to 12 Gy/fraction (fx) delivered over 1.5 to 2 weeks. Dose-limiting toxicity (DLT) was defined as any treatment-related grade 3 or worse predefined toxicity that occurred within the first year. MTD was defined as the SBRT dose at which the probability of DLT was closest to 20% without exceeding it. RESULTS One hundred twenty patients were accrued between February 2009 and September 2013. Patients were elderly, there were slightly more females, and the majority had a performance status of 0 to 1. Most cancers were T1 (65%) and squamous cell (45%). Organs closest to planning target volume/most at risk were the main bronchus and large vessels. Median follow-up was 37.9 months. Five patients experienced DLTs; MTD was 12.0 Gy/fx, which had a probability of a DLT of 7.2% (95% CI, 2.8% to 14.5%). Two-year rates for the 71 evaluable patients in the 11.5 and 12.0 Gy/fx cohorts were local control, 89.4% (90% CI, 81.6% to 97.4%) and 87.9% (90% CI, 78.8% to 97.0%); overall survival, 67.9% (95% CI, 50.4% to 80.3%) and 72.7% (95% CI, 54.1% to 84.8%); and progression-free survival, 52.2% (95% CI, 35.3% to 66.6%) and 54.5% (95% CI, 36.3% to 69.6%), respectively. CONCLUSION The MTD for this study was 12.0 Gy/fx; it was associated with 7.2% DLTs and high rates of tumor control. Outcomes in this medically inoperable group of mostly elderly patients with comorbidities were comparable with that of patients with peripheral early-stage tumors.
Is There a Need for a 6-Month Postradiosurgery Magnetic Resonance Imaging in the Treatment of Vestibular Schwannoma?
Perry, Avital , Graffeo, Christopher S. , Peris‐Celda, Maria , Cray, Nealey, Pollock, Bruce E. , Link, Michael J. , Carlstrom, Lucas P. , Hughes, Joshua D, Cray, Nealey M, Hughes, Joshua

Mayo Clinic

Neurosurgery | April 3, 2019 | Volume: 86 | Issue: 2 | Pages: 250-256

10.1093/neuros/nyz052 | PMID 30980077 Get It

Abstract BACKGROUND Stereotactic radiosurgery (SRS) is a common treatment modality for vestibular schwannoma (VS), with a role in primary and recurrent/progressive algorithms. At our institution, routine magnetic resonance imaging (MRI) is obtained at 6 and 12 mo following SRS for VS. OBJECTIVE To analyze the safety and financial impact of eliminating the 6-mo post-SRS MRI in asymptomatic VS patients. METHODS A prospectively maintained SRS database was retrospectively reviewed for VS patients with 1 yr of post-treatment follow-up, 2005 to 2015. Decisions at 6-mo MRI were binarily categorized as routine follow-up vs clinical action —defined as a clinical visit, additional imaging, or an operation as a direct result of the 6-mo study. RESULTS A total of 296 patients met screening criteria, of whom 53 were excluded for incomplete follow-up and 8 for NF-2. Nine were reimaged prior to 6 mo due to clinical symptoms. Routine 6-mo post-SRS MRI was completed by 226 patients (76% of screened cohort), following from which zero instances of clinical action occurred. When scaled using national insurance database-derived financials—which estimated the mean per-study charge for MRI of the brain with and without contrast at $1767—the potential annualized national charge reduction was approximated as $1 611 504. CONCLUSION For clinically stable VS, 6-mo post-SRS MRI does not contribute significantly to management. We recommend omitting routine MRI before 12 mo, in patients without new or progressive neurological symptoms. If extrapolated nationally to the more than 100 active SRS centers, thousands of patients would be spared an inconvenient, nonindicated study, and national savings in health care dollars would be on the order of millions annually.